JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

JNJ

225.85

-0.11%↓

ABT

91.74

-1.11%↓

MDT

83.27

+0.9%↑

120.69

-1.07%↓

VEEV

162.96

-2.86%↓

Strona główna・Stock List・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Closed

SectorHealthcare

31.85 0.25

Buy Sell

Overview

Share price change

24h

Current

Min

30.74

Max

Key metrics
By Trading Economics
Income	-28M 22M
Sales	4.3M 244M
P/E Sector Avg	10.897 60.328
Profit margin	9.224
Employees	293
EBITDA	-22M 52M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+33.45% upside

Dividends
By Dow Jones
Next Earnings	5 maj 2026

Market Stats
By TradingEconomics
Market Cap	161M 1.7B
Previous open	31.6
Previous close	31.85

News Sentiment

By Acuity

34%

66%

132 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

29.8 / N/A Support & Resistance

Harmony Biosciences Holdings Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 kwi 2026, 00:00 UTC

Major News Events

Australian Flash PMI Bounce in April Conceals Deeper Worries

22 kwi 2026, 23:33 UTC

Earnings

SK Hynix Posts Record Quarterly Results Amid AI Boom

22 kwi 2026, 22:40 UTC

Earnings

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

22 kwi 2026, 22:10 UTC

Acquisitions, Mergers, Takeovers

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

22 kwi 2026, 21:11 UTC

Earnings

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

22 kwi 2026, 21:01 UTC

Earnings

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

22 kwi 2026, 23:46 UTC

Market Talk

Global Equities Roundup: Market Talk

22 kwi 2026, 23:46 UTC

Market Talk

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

22 kwi 2026, 23:34 UTC

Market Talk

Major News Events

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

22 kwi 2026, 23:16 UTC

Earnings

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

22 kwi 2026, 23:15 UTC

Earnings

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

22 kwi 2026, 22:54 UTC

Earnings

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

22 kwi 2026, 22:54 UTC

Earnings

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

22 kwi 2026, 22:52 UTC

Earnings

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

22 kwi 2026, 22:51 UTC

Earnings

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

22 kwi 2026, 22:31 UTC

Earnings

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

22 kwi 2026, 22:31 UTC

Earnings

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

22 kwi 2026, 22:30 UTC

Earnings

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

22 kwi 2026, 22:30 UTC

Earnings

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

22 kwi 2026, 22:29 UTC

Earnings

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

22 kwi 2026, 22:28 UTC

Earnings

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

22 kwi 2026, 22:28 UTC

Earnings

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

22 kwi 2026, 22:27 UTC

Earnings

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

22 kwi 2026, 22:06 UTC

Market Talk

Earnings

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

22 kwi 2026, 21:55 UTC

Acquisitions, Mergers, Takeovers

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

22 kwi 2026, 21:47 UTC

Earnings

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 kwi 2026, 21:37 UTC

Earnings

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

22 kwi 2026, 21:34 UTC

Earnings

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

22 kwi 2026, 21:29 UTC

Earnings

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

22 kwi 2026, 21:20 UTC

Market Talk

Earnings

Tesla Expands Manufacturing to Chips -- Market Talk

Peer Comparison

Price change

Harmony Biosciences Holdings Inc Forecast

Price Target

By TipRanks

33.45% upside

12 Months Forecast

Average 42.89 USD 33.45%

High 72 USD

Low 25 USD

Based on 9 Wall Street analysts offering 12 month price targets forHarmony Biosciences Holdings Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

Buy

Hold

Sell

Based on 9 analysts giving stock ratings to Harmony Biosciences Holdings Inc - Dist in the past 3 months.

Technical Score

By Trading Central

29.8 / N/ASupport & Resistance

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

132 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.